Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Apolipoprotein L5 (APOL5) is a cytoplasmic protein belonging to the apolipoprotein L family, encoded within a gene cluster on chromosome 22[1][2][3][6][7]. APOL5 shares structural similarities with other APOL proteins (such as amphipathic alpha-helices), but has a more restricted tissue expression, with notable expression in the placenta and potentially specialized roles in lipid biochemistry[1]. Its primary molecular role is implicated in the movement of lipids within the cytoplasm and binding of lipids to organelles[2][3][7]. Functional studies indicate that, unlike some other APOL family members, APOL5 does not induce cytolysis but can insert into membranes under certain electrical and pH conditions to form cation-selective ion channels, suggesting roles in membrane dynamics and possibly in innate immunity[1]. Genetic studies suggest candidate associations with neuropsychiatric subtypes, such as specific forms of schizophrenia; however, its direct functional involvement in disease or as a therapeutic target remains unsubstantiated[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Apolipoprotein L5 (APOL5).